Independent Business – Venn Life positions skin care subsidiary for AIM flotation

Please link to the article below by John Mulligan which was posted in Oct 2016 by website.

The sale of subsidiary company Innoven for €5.3m, by Venn Life Sciences, to Integumen has allowed it to be in a position to float on London’s Alternative Investment market. Innoven are developing and marketing a living skin product. and the directors of Venn Life believe the sale will allow the group to concentrate on drug development and clinical research.

In addition to the acquisition of Innoven, Integumen is in the process of acquiring three additional businesses.

You can read the full article by clicking on the button below.

Share This Post!

If you are interested in becoming an Investor or seeking investment, then please contact us.